// Biotech and Pharma Therapeutics
This diet helped people lose twice as much weight, without eating less
August 5, 2025 / Minimally processed diet / Ultra-processed foods / Weight loss study / Food processing impact / Metabolic health outcomes
A long-term study found that individuals consuming minimally processed foods lost twice as much weight as those eating ultra-processed diets, despite equal calories and nutrients, highlighting food processing as a critical factor in weight and metabolic health.
5 Hot Health Care Topics You Won’t Want to Miss at the Civitas 2025 Annual Conference
August 5, 2025 / Health data integration / Real-time interoperability / Whole-person care / Community information exchange / Digital health conference
The Civitas 2025 Annual Conference spotlights key innovations in health data integration, real-time interoperability, privacy, and community-driven care models like CIEs and HDUs—advancing whole-person, value-based care and improved outcomes through collaborative digital health transformation.
Why Behavioral Science Is A Significant Untapped Resource For Many Health Plans, And How They Can Better Leverage It
August 5, 2025 / Behavioral science healthcare / Chronic disease management / Health plan innovation / Member engagement strategy / Healthcare cost reduction
Behavioral science remains underutilized in health plans despite its potential to improve chronic disease management, reduce costs, and enhance member engagement by addressing cognitive, social, and environmental drivers of health behaviors through more effective, evidence-based interventions.
David Altshuler, geneticist who helped transform Vertex, to retire next year
Dr. David Altshuler, Vertex Pharmaceuticals’ chief scientific officer and architect of its research evolution beyond cystic fibrosis into CRISPR and novel pain therapies, will retire in 2026, marking a pivotal leadership transition in the company’s scientific strategy.
The Promise of Digital Health and Remote Therapeutic Monitoring for Improving OUD Treatment Outcomes
Digital health tools, particularly Remote Therapeutic Monitoring (RTM), enhance treatment retention and adherence in opioid use disorder by enabling continuous, personalized engagement. Evidence shows RTM can improve outcomes in OUD and other chronic conditions by bridging gaps in care access.
// 4th Industrial Revolution
The Role of Analytics and AI-Driven Tools in Aligning Payers and Providers Around Value-Based Care Models
AI-driven tools and advanced analytics are transforming value-based care by aligning payers and providers around shared goals—enhancing care coordination, reducing costs, optimizing risk stratification, streamlining prior authorization, and improving outcomes through data-driven, patient-centered interventions across the care continuum.
Can amylin-based drugs upstage GLP-1 agonists?
Amylin analogs are emerging as promising obesity treatments, potentially surpassing GLP-1 agonists by offering effective weight loss with fewer gastrointestinal side effects and reduced risk of muscle loss—particularly as developers explore convenient oral formulations.
Engineering B cells to treat and study human disease
August 5, 2025 / Engineered B cells / B cell therapy / Immunotherapy innovation / Chronic disease treatment / Cancer cell therapy
Elation Health Expands Clinical-First AI Platform for Primary Care
August 5, 2025 / Primary care AI / Clinical workflow automation / EHR innovation platform / Physician burnout reduction / Value-based care tools
Elation Health has expanded its AI-powered, primary care-focused platform to streamline workflows, reduce clinician burden, and enhance patient care. Integrated directly into the EHR and billing systems, its tools support decision-making, documentation, communication, and value-based care delivery.
ShelterZoom Launches Spare Tire: Real-Time EHR Backup for Cybersecurity Resilience
ShelterZoom’s Spare Tire provides real-time, continuously syncing EHR backup to ensure uninterrupted healthcare operations during cyberattacks or outages. Unlike static backups, it maintains full workflows and auto-reintegrates data, enhancing cybersecurity resilience for hospitals and care facilities.
// Business & Markets
How Shockwave Medical sealed the deal that could put Johnson & Johnson back on top
August 4, 2025 / Shockwave Medical acquisition / Johnson & Johnson medtech / Cardiovascular device market / Medtronic divestiture diabetes / Medical device industry
Johnson & Johnson’s $13.1B acquisition of Shockwave Medical positions it to surpass Medtronic in global medtech revenue, driven by strong growth in cardiovascular devices and strategic expansion amid Medtronic’s planned divestiture of its diabetes division.
Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot
Hansa Biopharma’s imlifidase shows promise as a pretreatment to reduce immune responses to Sarepta’s gene therapy Elevidys in Duchenne muscular dystrophy, potentially addressing safety concerns like liver injury and expanding treatment eligibility.
Lilly confirms plan to sell New Jersey plant amid larger US production ramp-up
August 4, 2025 / Eli Lilly manufacturing / API production expansion / New Jersey plant sale / Injectable drug facilities / Pharmaceutical job growth
Eli Lilly plans to sell its Branchburg, NJ plant amid a $27B U.S. manufacturing expansion, including four new facilities focused on APIs and injectables, aiming to boost flexibility, support next-gen therapies, and create over 3,000 jobs.
Frazier Healthcare Partners Sells Elevate Patient Financial Solutions to Audax and Parthenon
Frazier Healthcare Partners has sold Elevate Patient Financial Solutions, a leading RCM platform for hospitals, to Audax and Parthenon. Elevate grew through strategic acquisitions and tech-driven expansion, offering solutions in enrollment, complex claims, revenue integrity, and patient payments.
Vertex plan to build on pain drug breakthrough hits hurdles
August 5, 2025 / Non-opioid pain therapy / Vertex Journavx update / Neuropathic pain treatment / VX-993 trial failure / FDA pain drug guidance
// Legal & Regulatory
Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain
August 5, 2025 / Journavx / Neuropathic pain / Vertex Pharmaceuticals / FDA decision / Diabetic neuropathy
Vertex will prioritize diabetic peripheral neuropathy (DPN) for Journavx after the FDA declined a broad label for peripheral neuropathic pain. A second Phase 3 DPN trial will proceed, delaying expansion into other neuropathic indications like lumbosacral radiculopathy.
Drugmakers score policy win in fight against 340B
August 4, 2025 / 340B / Drug rebates / PhRMA policy / Hospital funding / Drug pricing
A new Trump-era pilot program allows drugmakers to test replacing 340B discounts with rebates, a shift backed by PhRMA but criticized by hospitals for potentially raising upfront costs and delaying reimbursement for safety-net providers.
DOJ reaches $9.8M settlement with Illumina over cyber whistleblower claims
Illumina will pay $9.8M to settle DOJ claims it sold genomic sequencing systems with known cybersecurity flaws to federal agencies. The case highlights the growing importance of cybersecurity in protecting genetic data and federal health infrastructure.
FDA nod for expanded indication of Avtozma
The FDA has expanded approval of Celltrion’s Avtozma (tocilizumab-anoh) IV to treat cytokine release syndrome (CRS) in patients aged ≥2, aligning it fully with Roche’s Actemra IV across all U.S. indications, including RA, GCA, and COVID-19.
Court Blocks Sale of 54gene Assets Amid Founder-Investor Legal Battle
A Nigerian court has blocked the sale of 54gene’s assets, including genomic data from 100,000 individuals, amid legal claims by its founder alleging ethical breaches and investor misconduct in the biotech startup’s collapse and attempted dissolution.
// Research & Development
Its Own Reward: NEMT Services Meet Challenge for Special Needs Patients
Non-Emergency Medical Transportation (NEMT) is a vital yet often overlooked component of healthcare, especially for patients with disabilities or chronic conditions, ensuring reliable access to essential medical services and continuity of care.
Pfizer’s embattled obesity program loses another GLP-1 over poor data and strong competition
Pfizer has discontinued its last GLP-1 agonist for obesity, PF-06954522, due to underwhelming data and fierce competition. The company is refocusing efforts on alternative metabolic candidates and potential external acquisitions to stay competitive in the obesity drug market.
Alzheimer’s risk may start at the brain’s border, not inside it
August 4, 2025 / Alzheimer’s risk / Blood-brain barrier / Neurodegenerative disease / Brain immune cells / Vascular genetics
Johns Hopkins scientists grow a mini human brain that lights up and connects like the real thing
Johns Hopkins scientists developed a multi-region brain organoid with blood vessels and neural activity, enabling new insights into early brain development and diseases like autism and schizophrenia, while offering a platform for testing treatments beyond traditional animal models.
BioMarin touts promising early result for potential Voxzogo successor
August 5, 2025 / BioMarin / Achondroplasia treatment / Long-acting CNP / Voxzogo successor / Pediatric dwarfism
BioMarin’s BMN 333, a longer-acting CNP analog, showed strong pharmacokinetics and no safety issues in a Phase 1 trial, positioning it as a potentially superior successor to Voxzogo for treating achondroplasia in children.
// Politics
Mitigating Tariff-Related Expenses: Key Strategies to Know
August 5, 2025 / Medical devices / Tariff impact / Domestic manufacturing / Supply chain / U.S. reshoring
Best Circuits highlights how rising tariffs have spurred reshoring of U.S. medical device manufacturing, encouraging domestic design and production amid ongoing pricing, supply chain, and quality concerns tied to overseas operations, especially in China.
Trump administration to pilot 340B rebate model next year
The Trump administration will pilot a 340B rebate model allowing drugmakers to reimburse hospitals post-dispensing, shifting from upfront discounts. Critics, including the AHA, warn this change could jeopardize the program’s integrity and timely access to affordable medications.
Senate committee opposes Trump’s NIH cuts, proposes $400M budget increase
Healthcare Stocks Sent Mixed Signals As Deals And Politics Took Center Stage
Healthcare stocks showed mixed performance as investors responded to potential 250% tariffs on drugs, M&A activity, and earnings surprises. Policy shifts and consolidation are increasing uncertainty, pressuring pharmaceutical and biotech companies to adapt cost structures and global supply strategies.
Trump escalates demands that pharma companies lower their drug prices
President Trump demanded that 17 major pharma companies align U.S. drug prices with international benchmarks, urging lower Medicaid and Medicare pricing, direct distribution of key drugs, and repatriation of foreign earnings by September 29.